Rhythm Pharma Q2 FY26 net loss widens to $50.4 million; revenue rises 47% to $71.3 million
RYTM•Quarterly results
Rhythm Pharmaceuticals posted Q2 net product revenue of $71.3 million, up 47% from the year-ago quarter.
Net loss attributable to common stockholders widened to $50.4 million, or $0.73 per share, from $48.0 million, or $0.75 per share.
Full-year guidance
Rhythm guided for 2026 non-GAAP operating expenses of $363 million to $397 million, excluding stock-based compensation and fixed in-licensing consideration.
Expenses and launch update
Research and development expenses edged up to $43.4 million; selling, general and administrative expenses climbed to $67.4 million.
The U.S. IMCIVREE launch in acquired hypothalamic obesity logged more than 400 patient start forms from about 300 prescribers since the March 19 FDA approval.
